Drug
Aticaprant clinical trials
Also written JNJ-67953964 and CERC-501.
- studies test it
- 17
- open now
- 1
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the Aticaprant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
17 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
Janssen Research & Development, LLC (11) · Janssen Pharmaceutical K.K. (1) · Yale University (1) · Duke University (1) · Eli Lilly and Company (1) · Massachusetts General Hospital (1) · Andrew Krystal (1)
Studies
Open first, then newest update. How each study uses Aticaprant is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaRecruitingPhase 1Janssen Research & Development, LLCNCT07615426Written as Aticaprant
- A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)TerminatedPhase 3Janssen Research & Development, LLCNCT05518149Written as Aticaprant
- A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureTerminatedPhase 3Janssen Research & Development, LLCNCT06635135Written as Aticaprant
- A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantTerminatedPhase 3Janssen Research & Development, LLCNCT06514742Written as Aticaprant
- A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedPhase 3Janssen Research & Development, LLCNCT05550532Written as Aticaprant
- A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedPhase 3Janssen Research & Development, LLCNCT05455684Written as Aticaprant
- A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of DepressionCompletedPhase 2Janssen Research & Development, LLCNCT03559192Written as JNJ-67953964
- A Study of JNJ-67953964 in Healthy Japanese Adult Male ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT04791332Written as JNJ-67953964
- A Study of 14C JNJ-67953964 in Healthy Adult Male ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05197062Written as 14C-aticaprant
- A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05387759Written as Aticaprant Supratherapeutic Dose
- A Study in a Human Laboratory Model of Smoking BehaviorCompletedPhase 2Janssen Research & Development, LLCNCT02641028Written as CERC-501
- A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04185051Written as JNJ-67953964
- Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?CompletedPhase 2Yale UniversityNCT02800928Written as CERC-501
- Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2aCompletedPhase 2Duke UniversityNCT02218736Written as CERC-501
- Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionTerminatedPhase 2Massachusetts General HospitalNCT01913535Written as CERC-501
- FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 StudyWithdrawnPhase 1Andrew KrystalNCT02218775Written as LY2456302
- A Study of Brain Receptor Occupancy in Healthy SubjectsCompletedPhase 1Eli Lilly and CompanyNCT01232439Written as opioid receptor kappa antagonist
Codes
What other systems call Aticaprant · ClinicalTrials.gg INT000050
- MeSH (NLM) C000590915AticaprantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DE4G8X55F5ATICAPRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q18344482aticaprantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170144AticaprantOne source FDA
- DrugBank DB12341One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590915 | Aticaprant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DE4G8X55F5 | ATICAPRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18344482 | aticaprant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170144 | Aticaprant | One source FDA |
| DrugBank | DB12341 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.